Research scientists at Bayer HealthCare AG in Germany are optimizing a new chemical inhibitor for pulmonary arterial hypertension (PAH) treatment. The team of medicinal chemists generated a library of compounds centered around inhibiting human neutrophil elastase (HNE), a key driver of inflammation in PAH. After generating molecules that successfully inhibited…
It was once thought among doctors that patients with pulmonary hypertension, many of whom can’t even walk a short distance without being short of breath, shouldn’t exercise. Pulmonary hypertension is a disease that leads to high blood pressure in the arteries of the lungs. When this occurs, the right side of the…
An 18 year-long prospective study on the length of television watching and the risk of pulmonary embolism revealed a positive correlation between the length of time a person watches television per day and the risk of developing a possibly fatal pulmonary embolism. The study was presented at the …
In a new study titled “Symptom Interference Severity and Health-Related Quality of Life in Pulmonary Arterial Hypertension,” researchers determined which symptoms experienced by people with pulmonary arterial hypertension (PAH) are most self-limiting and interfering in daily quality of life. The study was published in the…
The recent announcement of positive results for the AMBITION trial testing combinatorial ambrisentan and tadalafil in patients with pulmonary arterial hypertension (PAH) is bringing more attention to the need to actively recruit participants for clinical trials. Without patients and clinicians interested in trying new treatments for a currently…
The European Society of Cardiology (ESC) together with the European Respiratory Society (ERS) recently launched a new treatment algorithm for pulmonary arterial hypertension in its updated pulmonary hypertension guidelines. The amended protocol aims to provide patients with the best chance of a positive clinical outcome despite being diagnosed with…
Gilead Sciences, Inc. recently announced the publication of data in The New England Journal of Medicine concerning the AMBITION trial evaluating the combination therapy of Letairis® (ambrisentan) and tadalafil for pulmonary arterial hypertension (PAH). The AMBITION trial (NCT01178073) is a multicenter, randomized, double-blind…
Actelion Pharmaceuticals Ltd recently announced in a press release that new data on its investigational drug selexipag (Uptravi®) and the approved macitentan (Opsumit®) for pulmonary arterial hypertension will be presented at the upcoming European Society of Cardiology (ESC) Congress in London, United Kingdom, August 29 to September…
In a new study entitled “Vagotomy attenuates bleomycin-induced pulmonary fibrosis in mice,” researchers investigated the role of the vagus nerve in pulmonary fibrosis pathogenesis. They established a mouse model and discovered that the vagus nerve regulates pulmonary fibrosis progression by controlling pro-fibrotic factors. The study was published in…
Results from a recent study published in the journal Circulation: Cardiovascular Imaging showed that pediatric patients with Pulmonary hypertension have reduced Left Ventricular strain/strain rate, predominantly within the septum, with relationships to invasive hemodynamics, right ventricular strain, and functional Pulmonary hypertension measures. Pulmonary hypertension (PH) is raised…
A new study recently published in the Chinese Medical Journal revealed that a 6-month warfarin treatment might not be sufficient as an effective therapy for patients with pulmonary embolism complicated by obstructive sleep apnea hypopnea syndrome (OSAHS). The study was conducted by researchers at Beijing Anzhen Hospital…
A new study published in the Journal of Cardiovascular Ultrasound revealed a new parameter linked to right ventricular function as a good prognostic tool for pulmonary arterial hypertension (PAH). The study is entitled “Impaired Global Right Ventricular Longitudinal Strain Predicts Long-Term Adverse Outcomes in…
Get regular updates to your inbox.
